A COVID moonshot: assessment of ligand binding to the SARS-CoV-2 main protease by saturation transfer difference NMR spectroscopy

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological cause of the coronavirus disease 2019, for which no effective antiviral therapeutics are available. The SARS-CoV-2 main protease (M-pro) is essential for viral replication and constitutes a promising therapeutic target. Many efforts aimed at deriving effective M-pro inhibitors are currently underway, including an international open-science discovery project, codenamed COVID Moonshot. As part of COVID Moonshot, we used saturation transfer difference nuclear magnetic resonance (STD-NMR) spectroscopy to assess the binding of putative M-pro ligands to the viral protease, including molecules identified by crystallographic fragment screening and novel compounds designed as M-pro inhibitors. In this manner, we aimed to complement enzymatic activity assays of M-pro performed by other groups with information on ligand affinity. We have made the M-pro STD-NMR data publicly available. Here, we provide detailed information on the NMR protocols used and challenges faced, thereby placing these data into context. Our goal is to assist the interpretation of M-pro STD-NMR data, thereby accelerating ongoing drug design efforts.

Automated summary

This article discusses efforts to develop inhibitors for the SARS-CoV-2 main protease and provides detailed information on using STD-NMR spectroscopy to assess the binding of potential M-pro ligands to the viral protease. By making the data public, the goal is to assist in accelerating drug design efforts.